Dark Genome Biotech HERVolution Therapeutics Announces $11.7M Series A to Advance Treatments for Cancer & Diseases of Aging
HERVs as therapeutic allies: Novel immune strategies for aging-related conditions
Once thought to be a collection of repetitive “junk DNA” with minimal biological purpose, the dark genome is home to genes that can impact cellular function and contribute to disease. Human endogenous retroviruses (HERVs) are a class of dark genome antigens comprising genetic remnants of ancient retroviruses that infected our ancestors. Typically dormant when we are young and healthy, HERVs can become active as we age or develop certain diseases, amplifying aging or contributing to progression of cancer, type 2 diabetes, and some neurodegenerative diseases.
At HERVolution, we are unlocking the hidden therapeutic potential of HERVs to deliver a new class of immune therapies. We have rationally redesigned HERVs to break immune tolerance, making these once-invisible antigens visible to the immune system and demonstrating human immune cell activation toward HERVs for the first time.
Our proprietary engineering platform drives a pipeline of off-the-shelf assets that empower the immune system to target HERVs implicated in aging-related diseases, with an initial focus on cancer, metabolic disease, and longevity.
Illuminating the path toward HERV-based immune therapies
We are a team of visionary researchers and seasoned drug developers uniquely equipped to unlock the therapeutic potential of HERVs, with deep expertise in immunology, virology, oncology, metabolic disease, protein engineering, platform technologies and portfolio development.
J. Robert Coleman, PhD, MBA
Chief Executive Officer
Peter Holst, MD, PhD
Chief Scientific Officer
Jan Villadsen
Chief Financial Officer
Anne-Marie Andersson, PhD
Chief Technology OfficerStay at the forefront of HERV science
HERVolution Therapeutics Appoints Biotech Builder J. Robert Coleman as CEO to Accelerate Groundbreaking Immunotherapies to Treat Dark Genome Targets in Cancer, Aging, and Neurodegeneration
HERVolution Therapeutics appoints Moderna Co-Founder and MIT Professor Robert S. Langer as Chair of its Scientific Advisory Board
United in our purpose to revolutionize treatment for aging-related diseases
As a team of trailblazers, we are steadfast in our pursuit of pioneering science to harness the power of HERVs and fuel a transformation in the treatment of complex diseases of aging. We foster a culture of open collaboration and shared success as we face challenges head on, leveraging diverse perspectives to unveil new discoveries on our journey to translate innovation into impact.
Ready to join the HERVolution?
